ZURICH–(BUSINESS WIRE)–Vivior a signé un accord avec Kochoptik, un opticien suisse de haute qualité. Les clients de Kochoptik porteront le moniteur de comportement visuel de Vivior, ce qui conduira à une recommandation de solution individualisée de s…
Author: Business Wire
Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension
MUMBAI, India & PRINCETON, N.J.–(BUSINESS WIRE)–#BAK–Sun Pharma’s XELPROS™ (latanoprost ophthalmic emulsion) 0.005% approved by the U.S. FDA
Riassunto: BioTime chiude per $43,2 milioni la transazione di vendita di azioni AgeX con Juvenescence
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc (NYSE American: BTX), un’azienda di biotecnologie di livello clinico che concentra la sua attività sulle malattie degenerative, ha annunciato quest’oggi di aver concluso la transazione annunciata in preced…
Samenvatting: BioTime sluit $43.2 miljoen AgeX aandelenverkooptransactie met Juvenescence
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), een biotechnologisch bedrijf in de klinische fase dat zich toelegt op degeneratieve ziekten, heeft vandaag aangekondigd dat het de eerder aangekondigde transactie met Juvenescence Li…
Resumen: BioTime cierra una transacción de 43,2 millones de dólares por la venta de acciones de AgeX con Juvenescence
ALAMEDA, California–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), una compañía de biotecnología clínica centrada en las enfermedades degenerativas, ha anunciado hoy que ha cerrado la transacción previamente anunciada con Juvenescence Limited, l…
BioTime clôture une transaction de vente d’actions AgeX de 43,2 millions USD avec Juvenescence
ALAMEDA, Californie–(BUSINESS WIRE)–BioTime, Inc. (NYSE American : BTX), une société de biotechnologie au stade clinique axée sur les maladies dégénératives, a annoncé aujourd’hui la clôture de la transaction annoncée précédemment avec Juvenescence L…
BioTime schließt Verkauf von AgeX-Anteilen an Juvenescence in Höhe von 43,2 Millionen USD ab
ALAMEDA, Kalifornien–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), ein klinisches Biotechnologie-Unternehmen mit Spezialisierung auf degenerative Erkrankungen, meldete heute den Abschluss der zuvor angekündigten Transaktion mit Juvenescence Lim…
STAAR Surgical Announces Approval by the FDA of the Visian Toric ICL for the Correction of Myopia with Astigmatism
MONROVIA, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that the FDA has granted approval of the PMA …
The Global $18bn Contact Lenses Market by 2024: Key Driver & Opportunity Analysis – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Contact Lenses Mask Market Analysis (2018-2024)” report has been added to ResearchAndMarkets.com’s offering. The Global Contact Lenses Market size is expected to reach $18 billion by 2024, rising at a market growth …
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab)…
Vivior Signs Agreement with Kochoptik to Evaluate Vivior’s System
ZURICH–(BUSINESS WIRE)–Vivior has signed an agreement with Kochoptik, a premium optical retailer in Switzerland. Kochoptik’s customers will wear Vivior’s Visual Behavior Monitor to provide a recommendation for an individualized vision care solution. …
Presbia to Participate in the XXXVI Congress of the European Society of Cataract & Refractive Surgeons and in the German Ophthalmological Society Congress
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in near-vision restoration, will participate in the XXXVI Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), Europe’s leading organiz…
Travecta Therapeutics Appoints Douglas C. Hicks as Chief Business Officer
PHILADELPHIA–(BUSINESS WIRE)–Travecta Therapeutics, an emerging biotech company developing a platform that leverages its proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents across the blood-brain barrier, ann…
Paragon BioTeck Reformulated FRESHKOTE®, Prompting Eyevance Acquisition
PORTLAND, Ore.–(BUSINESS WIRE)–Paragon BioTeck, recently completed the reformulation for FRESHKOTE® lubricant eye drops, purchased this week by Eyevance Pharmaceuticals.
Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
The Global Eyewear Market with Focus on Premium Eyewear (2018-2022) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Eyewear Market with Focus on The Premium Eyewear (2018-2022 Edition)” report has been added to ResearchAndMarkets.com’s offering. The global eyewear market has increased with a healthy growth rate over the years and…
More than 180 Children’s Hospital Los Angeles Physicians Named “Top Doctors” in Annual List Honoring the Region’s Most Esteemed Specialists
LOS ANGELES–(BUSINESS WIRE)–More than 180 Children’s Hospital Los Angeles physicians were named Top Doctors by Pasadena Magazine, honoring the region’s most esteemed specialists.
In Australia, NovaTears® Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On
HEIDELBERG, Germany–(BUSINESS WIRE)–#AFT–Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, is the manufacturer of NovaTe…
STAAR Surgical Announces EVO ICL Clinical Program for its 15th Annual Surgical Experts Summit in Vienna, Austria, from September 19 – 21, 2018
MONROVIA, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing the EVO ICL Clinical Program which will be pr…
The $65.25Bn Global Ophthalmic Devices Market to 2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Devices Market – Forecasts from 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering. The ophthalmic device market is projected to grow at a CAGR of 5.01% to reach US$65.248 billion in 2023 f…